Dagenham, United Kingdom

Keith Alfred Stuttle


Average Co-Inventor Count = 8.0

ph-index = 2

Forward Citations = 50(Granted Patents)


Company Filing History:


Years Active: 1997-1998

Loading Chart...
2 patents (USPTO):Explore Patents

Title: **The Innovations of Keith Alfred Stuttle: A Notable Inventor in Pharmaceutical Patents**

Introduction

Keith Alfred Stuttle, an accomplished inventor based in Dagenham, GB, has made significant contributions to the field of pharmaceuticals. With a total of two patents to his name, Stuttle’s work focuses on innovative compounds that demonstrate potential therapeutic applications, particularly in the realm of treating serious health conditions.

Latest Patents

Stuttle’s notable patents relate to compounds containing phenyl linked to aryl or heteroaryl by an aliphatic chain. These inventions are primarily directed at the pharmaceutical use of phenyl compounds for inhibiting tumor necrosis factor. Furthermore, they encompass the compounds' preparation, pharmaceutical compositions incorporating these compounds, and their application for inhibiting cyclic AMP phosphodiesterase. His innovative work highlights the potential for these compounds to contribute significantly to medical science.

Career Highlights

Stuttle is associated with Rhône-Poulenc Rorer, a respected company within the pharmaceutical industry. His career at this organization has been marked by a dedication to research and development, emphasizing his commitment to innovation and improving health outcomes through his discoveries.

Collaborations

Throughout his career, Stuttle has collaborated with various professionals in the field, including notable coworkers such as Garry Fenton and Andrew David Morley. These collaborations have likely facilitated the exchange of ideas and fostered an environment conducive to groundbreaking developments in pharmaceuticals.

Conclusion

In summary, Keith Alfred Stuttle’s contributions to pharmaceutical innovations, marked by his two patents, underscore his role as a pivotal figure in the development of therapeutic compounds. His work, particularly in inhibiting tumor necrosis factor and cyclic AMP phosphodiesterase, positions him as a valuable inventor within the healthcare sector. As research continues, it will be exciting to see how his inventions evolve and impact medical treatment.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…